Search results for "030215 immunology"

showing 10 items of 670 documents

TGF-β signalling is required for CD4⁺ T cell homeostasis but dispensable for regulatory T cell function.

2013

Signalling by the cytokine TGF-β regulates mature CD4+ T cell populations but is not involved in the survival and function of regulatory T cells.

Autoimmunity10263 Institute of Experimental ImmunologyT-Lymphocytes RegulatoryMiceInterleukin 210302 clinical medicineTransforming Growth Factor beta2400 General Immunology and MicrobiologyHomeostasisCytotoxic T cellIL-2 receptorBiology (General)0303 health sciencesGeneral Neuroscience2800 General NeurosciencePeripheral toleranceFOXP3ColitisNatural killer T cell3. Good healthCell biologymedicine.anatomical_structureGeneral Agricultural and Biological SciencesResearch ArticleSignal TransductionRegulatory T cellQH301-705.5Receptors Antigen T-Cell610 Medicine & health1100 General Agricultural and Biological SciencesThymus GlandBiologyGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciences1300 General Biochemistry Genetics and Molecular BiologyLymphopeniamedicineAnimalsAntigen-presenting cellCell Proliferation030304 developmental biologyInflammationIntegrasesGeneral Immunology and MicrobiologyReproducibility of ResultsMice Inbred C57BLTamoxifenImmunologyNIH 3T3 Cells570 Life sciences; biologyGene Deletion030215 immunologyPLoS Biology
researchProduct

Type-IIA secreted phospholipase A2 is an endogenous antibiotic-like protein of the host.

2010

International audience; Type-IIA secreted phospholipase A(2) (sPLA(2)-IIA) has been proposed to play a role in the development of inflammatory diseases. It has been shown to release arachidonic acid, the precursor of proinflammatory eicosanoids, to hydrolyze phospholipids of pulmonary surfactant, and to bind to specific receptors located on cell surface membranes. However, the most established biological role of sPLA(2)-IIA is related to its potent bactericidal property in particular toward Gram-positive bacteria. This enzyme is present in animal and human biological fluids at concentrations sufficient to kill bacteria. Human recombinant sPLA(2)-IIA is able to kill Gram-positive bacteria at…

Bacterial Toxinsmedicine.disease_causeGroup II Phospholipases A2BiochemistryMicrobiologyAnthraxMice03 medical and health scienceschemistry.chemical_compound0302 clinical medicineImmune systemPhospholipase A2PhosphatidylcholinemedicineAnimalsHumansEscherichia coli030304 developmental biologyAntigens Bacterial0303 health sciencesPhospholipase AArachidonic AcidbiologyDrug Resistance MicrobialPathogenic bacteriaGeneral Medicinebiology.organism_classificationAnti-Bacterial Agents3. Good healthBacillus anthracisBiochemistrychemistryBacillus anthracisHost-Pathogen Interactionsbiology.protein[SDV.IMM.VAC]Life Sciences [q-bio]/Immunology/VaccinologyBacteria030215 immunology
researchProduct

Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study.

2018

Splenectomy in addition to immunotherapy with rituximab can provide quick and sometimes durable disease control in patients with splenic marginal zone lymphoma (SMZL). However, systemic chemotherapy is ultimately required in many cases. The BRISMA (Bendamustine-rituximab as first-line treatment of splenic marginal zone lymphoma)/IELSG (International Extranodal Lymphoma Study Group)36 trial is an open-label, single arm phase II study designed by the IELSG in cooperation with the Fondazione Italiana Linfomi and the lymphoma Study Association according to Simon's two-stage method. The primary endpoint was complete response rate. Fifty-six patients with SMZL diagnosis confirmed on central revis…

BendamustineAdultMalemedicine.medical_specialtyPhases of clinical researchNeutropeniaGastroenterologyDisease-Free SurvivalDrug Administration ScheduleSettore MED/15 - Malattie Del Sangue03 medical and health sciences0302 clinical medicineInternal medicinefirst-line therapyAntineoplastic Combined Chemotherapy ProtocolsMedicineBendamustine HydrochlorideHumansSplenic marginal zone lymphomabendamustineAgedbusiness.industrySplenic NeoplasmsHematologyLymphoma B-Cell Marginal ZoneMiddle Agedmedicine.diseaseLymphomaimmunochemotherapyRegimenTreatment Outcome030220 oncology & carcinogenesisbendamustine; first-line therapy; immunochemotherapy; rituximab; Splenic Marginal Zone Lymphoma; HematologySplenectomyRituximabFemaleSplenic Marginal Zone LymphomaNeoplasm Recurrence LocalbusinessRituximabFebrile neutropenia030215 immunologymedicine.drugBritish journal of haematology
researchProduct

Functionally active complement proteins C6 and C7 detected in C6- and C7-deficient individuals

1991

SUMMARYTwo sensitive sandwich ELISAs based on monoclonal antibodies directed to native C6 and C7 allowed the detection and quantitation of these complement proteins in 20 out of 37 serum samples from individuals who had previously been classified as deficient in these proteins as assessed by immunochemical and/or functional assays. Furthermore, serum from four C6-deficient and one combined C6-/C7-deficient individual showed an increase in the terminal complement complex (TCC) and a decrease in native C6 and C7 after complement activation as assayed by specific ELISAs. Despite their (incomplete) deficiencies, these individuals therefore possess functionally active terminal complement protein…

Blood Bactericidal Activitymedicine.drug_classImmunoblottingImmunologyEnzyme-Linked Immunosorbent AssayBiologyMonoclonal antibodyComplement Hemolytic Activity AssaySpecimen Handling03 medical and health sciences0302 clinical medicineTerminal complement complexImmunopathologymedicineHumansImmunology and AllergyComplement ActivationVolume concentration030304 developmental biology0303 health sciencesTemperatureZymosanAntibodies MonoclonalComplement deficiencyComplement C9Serum samplesmedicine.diseaseMolecular biologyComplement C7Complement C63. Good healthComplement (complexity)Complement systemImmunologyElectrophoresis Polyacrylamide GelResearch Article030215 immunologyClinical and Experimental Immunology
researchProduct

The Gut Microbiota as an Influencing Factor of Arterial Thrombosis

2018

The mutualistic gut microbiota does not only impact the development and function of various immune cell types, but it also influences the function of the hepatic vascular endothelium and prothrombotic platelet function. With germ-free mouse models, we have demonstrated that gut-derived microbial-associated molecular patterns could stimulate hepatic von Willebrand factor (VWF) synthesis and plasmatic VWF levels through Toll-like receptor-2 (TLR2), thus defining the extent of platelet deposition to the subendothelial matrix of the ligation-injured common carotid artery. In addition to the microbiota-derived choline metabolite trimethylamine N-oxide and the microbiota's regulatory role on the …

Blood Platelets030204 cardiovascular system & hematologyGut floradigestive system03 medical and health sciences0302 clinical medicineImmune systemVon Willebrand factorAnimalsHumansPlateletInnate immune systembiologyEndothelial CellsThrombosisArteriesHematologybiology.organism_classificationGastrointestinal MicrobiomeTLR2CoagulationImmunologybiology.proteinSignal transductionSignal Transduction030215 immunologyHämostaseologie
researchProduct

Buffy coat-derived platelets cryopreserved using a new method: Results from in vitro studies

2018

Abstract Cryopreservation for the long-term storage of platelets (PLTs) is a useful method to overcome the limits of platelet shortage. This is an in vitro prospective study to evaluate the count, viability, and function of buffy coat-derived pooled platelet concentrates (BC-PLTs), treated with dimethyl sulphoxide (DMSO) and cryopreserved (CRY BC-PLTs) at −80 °C with a modified Valeri method. PLTs were stored in 6% DMSO with a patented kit. Overall, 49 BC-PLTs from 245 healthy volunteer donors were prepared, cryopreserved, and analysed before and after 3, 6, and 9 months of storage. In flow cytometry, a statistically significant reduction in CD 42b (92.7 ± 4.29% at T0 vs. 23.6 ± 27.5% at T3…

Blood PlateletsCryopreservationmedicine.diagnostic_testChemistryIn vitro studyEconomic shortageHematologyBuffy coat030204 cardiovascular system & hematologyCryopreserved plateletThrombin generationCryopreservationIn vitroFlow cytometryAndrology03 medical and health sciences0302 clinical medicineViabilityBlood Buffy CoatHealthy volunteersmedicineHumansPlateletDMSO030215 immunologyTransfusion and Apheresis Science
researchProduct

Buffy coat-derived platelets cryopreserved using a new method: Results from a pivotal clinical trial on thrombocytopenic patients with acute leukaemia

2019

Abstract The administration of cryopreserved platelets (PLTs) may overcome the limits of platelet shortage and availability, especially during some seasons or in specific contexts like rural areas. After in vitro validation studies, ad hoc prepared buffy coat-derived pooled platelet concentrates (BC-PLTs), treated with dimethyl sulphoxide (DMSO) and cryopreserved (CRY BC-PLTs) at -80 °C with a modified Valeri method, were transfused in patients with severe thrombocytopenia secondary to chemotherapy for acute leukaemia (AL). Five inpatients were enrolled in the pivotal clinical trial NCT02032134: 4 males and 1 female with a mean age of 71 years (range: 65–80). Four patients were diagnosed wi…

Blood PlateletsMalemedicine.medical_specialtymedicine.medical_treatmentPlatelet TransfusionBuffy coat030204 cardiovascular system & hematologyAcute leukaemiaCryopreservation03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansPlateletAdverse effectAgedAged 80 and overCryopreservationChemotherapybusiness.industryTransfusionThrombinSevere thrombocytopeniaThrombosisHematologyCryopreserved plateletThrombocytopeniaSevere thrombocytopeniaClinical trialLeukemia Myeloid AcuteBlood PreservationConcomitantBlood Buffy CoatFemaleSafetybusiness030215 immunologyTransfusion and Apheresis Science
researchProduct

High-throughput elucidation of thrombus formation reveals sources of platelet function variability

2019

In combination with microspotting, whole-blood microfluidics can provide high-throughput information on multiple platelet functions in thrombus formation. Based on assessment of the inter-and intra-subject variability in parameters of microspot-based thrombus formation, we aimed to determine the platelet factors contributing to this variation. Blood samples from 94 genotyped healthy subjects were analyzed for conventional platelet phenotyping: i.e. hematologic parameters, platelet glycoprotein (GP) expression levels and activation markers (24 parameters). Furthermore, platelets were activated by ADP, CRP-XL or TRAP. Parallel samples were investigated for whole-blood thrombus formation (6 mi…

Blood PlateletsPlatelet AggregationPlatelet Function TestsDISORDERSIntegrinPlatelet Membrane GlycoproteinsADHESIONPlatelet membrane glycoproteinArticleImmunophenotypingFlow cytometry03 medical and health sciences0302 clinical medicinePlatelet Biology & Its DisordersmedicineHumansPlateletPlatelet activationThrombuschemistry.chemical_classificationmedicine.diagnostic_testbiologyPlatelet CountThrombosisHematologyFlow CytometryPlatelet Activationmedicine.diseaseDIFFERENCEHigh-Throughput Screening AssaysCell biologychemistrybiology.proteinGPVIGlycoproteinBiomarkers030215 immunologyRESPONSESHaematologica-the Hematology Journal
researchProduct

New Insights into Platelet Signalling Pathways by Functional and Proteomic Approaches

2018

As circulating sentinels of vascular integrity, platelets act as crucial haemostatic cells as well as important inflammatory and immune cells, whereas under pathological conditions platelets drive thrombotic as well as non-thrombotic diseases related to chronic inflammation. In addition, platelets serve as an important cellular model to study the biology and pharmacology of signal transduction pathways. Platelet inhibition and activation responses are mediated by multiple signalling networks, which are tightly regulated by balanced catalysis of protein phosphorylation and dephosphorylation through protein kinases and protein phosphatases, respectively. However, we are only at the beginning …

Blood PlateletsProteomicsKinaseInflammationHematology030204 cardiovascular system & hematologyBiologyPhosphoproteinsPlatelet ActivationProteomicsCell biology03 medical and health sciences0302 clinical medicinemedicineHumansKinomePlateletProtein phosphorylationPlatelet activationSignal transductionmedicine.symptomProtein KinasesSignal Transduction030215 immunologyHämostaseologie
researchProduct

Potential of Multidimensional, Large-scale Biodatabases to Elucidate Coagulation and Platelet Pathways as an Approach towards Precision Medicine in T…

2019

Cardiovascular and especially thrombotic diseases remain a major cause of morbidity and mortality worldwide. In past years, significant improvements in understanding disease processes, risk assessment, and prediction of clinical outcome in the field of thrombosis and haemostasis have been made by using large-scale biodatabases. These important research resources enable a comprehensive research approach by integrating clinical, environmental, genomic, and molecular information. Cutting edge, high throughput technologies open new data dimensions for clinical large-scale investigations. Joining multiple information levels from several pathophysiological pathways in contrast to a single marker …

Blood Plateletsmedicine.medical_specialtyDatabases Factualbusiness.industryThrombosisHematologyDisease030204 cardiovascular system & hematologyDisease pathogenesisPrecision medicine03 medical and health sciences0302 clinical medicineCoagulationmedicineHumansPlateletThrombotic diseasePrecision MedicineRisk assessmentIntensive care medicinebusinessBlood CoagulationVenous thromboembolismBiomarkers030215 immunologyHämostaseologie
researchProduct